Table 3. Griseofulvin levels in plasma and RBCs.
| Study and cohort | Peak griseofulvin levels (μg/L)a (range)b | Coefficient of variation (%) | p valuec |
|---|---|---|---|
| Plasma | 0.013 | ||
| ex vivo study 1,000 mg dose Plasma | 1,830 (1,776, 1,884) | 3 | |
| ex vivo study 2,000 mg dose Plasma | 1,234 | NA | |
| IBSM study Cohort 1 Plasma | 1,378 (1,201, 1,588) | 12.1 | |
| IBSM study Cohort 2 Plasma | 1,079 (821, 1,337) | 33.8 | |
| RBCs | 0.21 | ||
| ex vivo study 1,000 mg dose RBC | 110 (59, 143) | 40.9 | |
| ex vivo study 2,000 mg dose RBC | 63 | NA | |
| IBSM study Cohort 1 RBC | 149 (123, 184) | 20.2 | |
| IBSM study Cohort 2 RBC | 86 (55, 117) | 51.0 |
aPeak griseofulvin levels are expressed as average.
bRange values for the 2,000 mg dose of the ex vivo study are not provided because only one subject was dosed.
cANOVA was used to compare peak griseofulvin levels values between cohorts (p value was significant if p < 0.05). The 2,000 mg dose of the ex vivo study was not included in this analysis since this group had only one subject and therefore was not appropriate to be included in the analysis. NA, not analyzed.